Yervoy or Ipilimumab

Yervoy or Ipilimumab
New ’biologic’ drug made by Bristol Myers Squib. This targets melanoma and costs a whopping 24,000 pounds or $36,000 US a month. The mean increased survival time in research was 3 months. 

Approved by FDA in March 2011: Yervoy is a monoclonal antibody that blocks a molecule known as cytotoxic T-lymphocyte antigen or CTLA-4. CTLA-4 may play a role in slowing down or turning off the body’s immune system, affecting its ability to fight off cancerous cells. Yervoy may work by allowing the body’s immune system to recognize, target, and attack cells in melanoma tumors. The drug is administered intravenously.

Work has also taken place with lung cancer. Readers might go to http://cancergrace.org/lung/tag/ipilimumab/ for more information, under the heading ’Immunotherapy in Lung cancer can we deliver on the promise?’

 

 

 

 

Learn about your cancer drugs.
CancerAcitve Logo
Subscribe (Free e-Newsletter)

Join Our
Newsletter

Join Our Newsletter Signup today for free and be the first to get notified on new updates.